We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)
References
1
1.Zavascki, AP, Goldani, LZ, Li, J, Nation, RL. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother2007;60:1206–1215.CrossRefGoogle ScholarPubMed
2
2.Nation, RL, Li, J. Colistin in the 21st century. Curr Opin Infect Dis2009;22:535–543.Google Scholar
3
3.Streit, JM, Jones, RN, Sader, HS, Fritsche, TR. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). Int J Antimicrob Agents2004;24:111–118.Google Scholar
4
4.Kontopidou, F, Plachouras, D, Papadomichelakis, E, et al. Colonization and infection by colistin-resistant gram-negative bacteria in a cohort of critically ill patients. Clin Microbiol Infect2011; 17: E9–E11.Google Scholar
5
5.World Health Organization. Guidelines for DDD Classification and DDD Assignment 2010. Oslo: World Health Organization, 2009.Google Scholar